Abstract | BACKGROUND: METHODS: We conducted a pilot trial with 6 patients who were initially diagnosed with systemic DLBCL with CNS involvement. Patients were treated with a systemic MTX plus R- CHOP regimen. RESULTS: The overall response rate was 4/6 (66.7%). The CNS response rate and systemic response rate were 4/6 (66.7%) and 5/6 (83.3%), respectively. The median response duration of the 4 patients with complete remission at completion was 25.5 months, and the median survival of all patients was 25.1 months. CNS lesions progressed in all relapsed and refractory patients, while systemic disease progression was observed in 1 patient. No fatal hematologic adverse effects, hepatotoxicity or nephrotoxicity were observed. CONCLUSIONS: The dose of systemic MTX (1∼1.5 g/m(2)) or dose intensity (4-week interval in 4 patients) used in this trial was considered insufficient. Therefore, the dose of MTX or interval of each chemotherapy cycle should be modified in future trials to control CNS disease involved with DLBCL.
|
Authors | Kwai Han Yoo, Ji Yun Lee, Sung Hee Lim, Young Hyeh Ko, Seok Jin Kim, Won Seog Kim |
Journal | Acta haematologica
(Acta Haematol)
Vol. 133
Issue 2
Pg. 179-82
( 2015)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 25323539
(Publication Type: Journal Article)
|
Copyright | © 2014 S. Karger AG, Basel. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- R-CHOP protocol
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
- Methotrexate
|
Topics |
- Aged
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Disease-Free Survival
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, mortality, pathology)
- Male
- Methotrexate
(administration & dosage, adverse effects)
- Middle Aged
- Nervous System Diseases
(drug therapy, mortality, pathology)
- Pilot Projects
- Prednisone
(administration & dosage, adverse effects)
- Rituximab
- Survival Rate
- Time Factors
- Vincristine
(administration & dosage, adverse effects)
|